Free Download of The Capitol Forum ' s Report: " Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain "

In 2020, I wrote a blog post entitled " It ' s the Rx rebates, stupid! " (seehttps://blog.sstrumello.com/2020/09/its-rx-rebates-stupid.html for the post) in which I revealed the reason everyone was overpaying for insulin was because of rebating paid by insulin-makers to secure PBM formulary placement. Novo Nordisk revealed to its investors that it was spending 74% of its gross U.S. sales in the form of legally-exempted rebate kickbacks paid to PBMs. The good news is thanks to a series of actions by a number of different parties, the insulin PBM rebate price bubble finally burst whenLilly, followed byNovo Nordisk and thenSanofi all announced they would slash U.S. insulin list prices, and to pay for that, they would be opting out of the PBM commercialization channel for insulin. The price cuts are expected to happen at latest in early 2024. I recently blogged that we ' re seeing some early signs ofa similar phenomenon in the anti-inflammatory biologic known by the brand-name Humira with a similar bubble burst in prices for that particular medicine.Today, I am recommending my readers consider downloading a free report from The Capitol Forum. Details are provided at the end of this post. The Capital Forum describes itself this way:" We are an investigative news organization providing our subscribers with detail-oriented reporting on antitrust, merger control, corporate investigations, and energy.Our work combines cutting edge breaking news with in-depth analysis to better inform ...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain report The Capitol Forum Source Type: blogs